- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | CNS Pharmaceuticals, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 31.03. | CNS Pharmaceuticals, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 11.03. | CNS Pharma wipes glioblastoma pipeline clean in strategic pivot to fresh neurology, oncology targets | 1 | FierceBiotech | ||
| 11.03. | CNS Pharmaceuticals shifts focus to neurology, oncology assets | 1 | Investing.com | ||
| 11.03. | Strategiewechsel bei CNS Pharmaceuticals: Fokus auf Neurologie und Onkologie | 2 | Investing.com Deutsch | ||
| CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 11.03. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline | 446 | ACCESS Newswire | Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing marketsStrategic transformation... ► Artikel lesen | |
| 11.03. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 02.03. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.03. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team | 281 | ACCESS Newswire | Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNSNewly formed executive team is committed to execution and company... ► Artikel lesen | |
| 27.02. | CNS Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 17.02. | CNS Pharmaceuticals ernennt drei neue Führungskräfte im Zuge strategischer Neuausrichtung | 3 | Investing.com Deutsch | ||
| 17.02. | CNS Pharmaceuticals appoints three new executives to leadership team | 2 | Investing.com | ||
| 17.02. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 17.02. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation | 479 | ACCESS Newswire | New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value Creation HOUSTON, TX / ACCESS... ► Artikel lesen | |
| 27.01. | CNS Pharmaceuticals' new CEO outlines strategic overhaul | 2 | Investing.com | ||
| 27.01. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Issues Letter to Shareholders | 296 | ACCESS Newswire | Newly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS PharmaceuticalsStrategic Focus, Pipeline Optimization and Formalizing Roadmap for Near and Long-Term... ► Artikel lesen | |
| 17.12.25 | CNS Pharmaceuticals names Rami Levin as new CEO following John Climaco's departure | 2 | Seeking Alpha | ||
| 17.12.25 | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.12.25 | Führungswechsel bei CNS Pharmaceuticals: Rami Levin wird neuer CEO | 9 | Investing.com Deutsch | ||
| 17.12.25 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces CEO Transition | 411 | ACCESS Newswire | Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company")... ► Artikel lesen |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 16,115 | -24,94 % | Summit Therapeutics falls after update on Akeso-partnered lung cancer trial | ||
| ERASCA | 10,000 | -6,10 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,720 | -1,85 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer | Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated... ► Artikel lesen | |
| HEMAB THERAPEUTICS | 34,130 | 0,00 % | Hemab Therapeutics, Inc.: Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering | CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,960 | -3,05 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| COGENT BIOSCIENCES | 36,630 | +2,35 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 323,50 | +1,46 % | Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide | ||
| JANUX THERAPEUTICS | 14,340 | -0,21 % | Janux Therapeutics, Inc. - 8-K, Current Report | ||
| KINIKSA PHARMACEUTICALS | 55,23 | +2,70 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| CG ONCOLOGY | 66,21 | -0,79 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| COMPASS THERAPEUTICS | 1,960 | +10,73 % | Morning Market Movers: Sagimet Biosciences, Compass Therapeutics, Oruka Therapeutics, Veradermics See Big Swings | SAN DIEGO (dpa-AFX) - At 8:00 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 42,110 | +1,59 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| ZENAS BIOPHARMA | 19,360 | +0,21 % | Zenas BioPharma rises as CEO continues insider purchases | ||
| MINERALYS THERAPEUTICS | 29,300 | +9,94 % | Mineralys Therapeutics: TD Cowen startet Coverage mit Kaufempfehlung und sieht Blockbuster-Potenzial | ||
| ANNEXON | 5,750 | -2,04 % | Annexon Biosciences: Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones | ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with... ► Artikel lesen |
CNS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,08 % bei einem Aktienkurs von 2,340 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CNS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.